Company intelligence / Profile preview
TheraSid Bioscience
Seongnam-si, Gyeonggi-do, South Korea
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
The company's lead pipeline candidate TB-840 is in Phase 1 and preparing for a pre-IND meeting for Phase 2a clinical trials in the US and Korea for NASH/MASH treatment.
- Therapeutic areas
- GastroenterologyNeurologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Insilico Medicine (collaboration for AI-driven MASH therapeutics)
Beyond the preview
Go deeper on TheraSid Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TheraSid Bioscience.